$45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Provided legislative advocacy specific to the payment of innovative drugs, such as phosphate binders and anemia management drugs in the Medicare End-Stage Renal Dialysis Prospective Payment System (ESRD PPS). Provided legislative advocacy specific to the payment of innovative drugs, such as phosphate binders and anemia management drugs in the Medicare End-Stage Renal Dialysis Prospective Payment System (ESRD PPS)."
You can find more data on corporate lobbying on Quiver Quantitative.
AKBA Insider Trading Activity
AKBA insiders have traded $AKBA stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AKBA stock by insiders over the last 6 months:
- ERIK OSTROWSKI (SVP, CFO, CBO & Treasurer) sold 41,314 shares for an estimated $151,622
- RICHARD C MALABRE (SVP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 28,334 shares for an estimated $107,219.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AKBA Hedge Fund Activity
We have seen 110 institutional investors add shares of AKBA stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,041,798 shares (+19.8%) to their portfolio in Q2 2025, for an estimated $11,072,144
- GREAT POINT PARTNERS LLC removed 2,987,925 shares (-60.1%) from their portfolio in Q2 2025, for an estimated $10,876,047
- AIGH CAPITAL MANAGEMENT LLC removed 2,925,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,647,000
- MPM BIOIMPACT LLC added 2,889,125 shares (+inf%) to their portfolio in Q2 2025, for an estimated $10,516,415
- MORGAN STANLEY added 2,658,456 shares (+99.2%) to their portfolio in Q2 2025, for an estimated $9,676,779
- NUVEEN, LLC added 2,358,263 shares (+673.0%) to their portfolio in Q2 2025, for an estimated $8,584,077
- VANGUARD GROUP INC added 1,925,663 shares (+15.2%) to their portfolio in Q2 2025, for an estimated $7,009,413
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AKBA Analyst Ratings
Wall Street analysts have issued reports on $AKBA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/04/2025
- Leerink Partners issued a "Outperform" rating on 04/28/2025
To track analyst ratings and price targets for AKBA, check out Quiver Quantitative's $AKBA forecast page.
AKBA Price Targets
Multiple analysts have issued price targets for $AKBA recently. We have seen 2 analysts offer price targets for $AKBA in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $8.0 on 06/04/2025
- Roanna Ruiz from Leerink Partners set a target price of $7.0 on 04/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
